
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is supported by strong demand in pediatric and rare-disease testing, with Q3 volume up 25% year over year and Q2 revenue of $114 million, while management and the analyst both frame the rare-disease end market as robust. Its long-term outlook is strengthened by a growing shift from exomes to genomes, an Infinity database built over 25 years with more than 1 million exomes/genomes, 80% share in its core medical geneticist call point, and new coverage wins such as Medi-Cal and Carelon that should improve reimbursement visibility. Near-term execution is uneven because of RCM and EMR onboarding and an ASP headwind, but the company’s leadership refresh, gross margin expansion potential, and multiple growth catalysts in 2026-2027 support the positive stance.
Bears say
GeneDx Holdings is facing a less attractive fundamental setup because management lowered its 2026 volume outlook to at least 28% from 30%+, and even with reaffirmed 2026 revenue of $475 million to $490 million, Q4’26 revenue of $135 million still came in below expectations. The bigger concern is reimbursement risk: the company estimated ~45% of revenue could be hit by a 15% CLFS price cut in 2027, creating an implied 6.75% revenue headwind and forcing cuts to revenue estimates for 2026, 2027, and 2028. Although it is investing in pediatricians, the NICU, and newborn screening, those opportunities add execution risk while 2027 adjusted net income fell to just $2 million from $15 million previously, underscoring margin and earnings pressure.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GeneDx Holdings Corp (WGS) Forecast
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares